BACKGROUND: The prognosis of high-grade glioma in children is poor. PURPOSE: Interferon-gamma may increase the immune surveillance of glioma cells. Earlier clinical evidence had shown that low dose cyclophosphamide (CPM) increased immune response. METHODS: After induction treatment with simultaneous radiation and chemotherapy, patients were treated with individually increasing interferon-gamma (IFN-gamma) doses starting from 25 microg/m2/d s.c. increasing up to a maximum of 175 microg/m2/d within 7 weeks. Cyclophosphamide was given at 300 mg/m2 i.v. every 21 days. Forty pediatric glioma patients were enrolled (median age: 8.5 year, male: n = 22). Tumor locations included cerebral cortex (n = 8), basal ganglia (n = 4), brainstem (n = 24), cerebellum (n = 3), spinal cord (n = 1). Histologies were GBM (n = 14), AA (n = 14), LGG (n = 2, diffuse intrinsic pontine glioma). There was grade IV toxicity for thrombocytopenia (10%) and leucopenia (2.5%), grade III toxicity for central nervous (2.5%) and hepatic (5%) side effects, no toxic death. The observation time of the six surviving patients was: 1.2, 1.9, 4.2, 4.4, 4.6 and 4.7 years respectively. The median overall survival (1 year) was not significantly different from a historical control group (0.8 years). The survival of pontine gliomas appeared even inferior when compared to the previous protocol (n.s.). CONCLUSION: Maintenance treatment with IFN-gamma and low dose CPM has no sufficient beneficial effect for the treatment of high-grade glioma.
BACKGROUND: The prognosis of high-grade glioma in children is poor. PURPOSE:Interferon-gamma may increase the immune surveillance of glioma cells. Earlier clinical evidence had shown that low dose cyclophosphamide (CPM) increased immune response. METHODS: After induction treatment with simultaneous radiation and chemotherapy, patients were treated with individually increasing interferon-gamma (IFN-gamma) doses starting from 25 microg/m2/d s.c. increasing up to a maximum of 175 microg/m2/d within 7 weeks. Cyclophosphamide was given at 300 mg/m2 i.v. every 21 days. Forty pediatric gliomapatients were enrolled (median age: 8.5 year, male: n = 22). Tumor locations included cerebral cortex (n = 8), basal ganglia (n = 4), brainstem (n = 24), cerebellum (n = 3), spinal cord (n = 1). Histologies were GBM (n = 14), AA (n = 14), LGG (n = 2, diffuse intrinsic pontine glioma). There was grade IV toxicity for thrombocytopenia (10%) and leucopenia (2.5%), grade III toxicity for central nervous (2.5%) and hepatic (5%) side effects, no toxic death. The observation time of the six surviving patients was: 1.2, 1.9, 4.2, 4.4, 4.6 and 4.7 years respectively. The median overall survival (1 year) was not significantly different from a historical control group (0.8 years). The survival of pontine gliomas appeared even inferior when compared to the previous protocol (n.s.). CONCLUSION: Maintenance treatment with IFN-gamma and low dose CPM has no sufficient beneficial effect for the treatment of high-grade glioma.
Authors: Sabine Wagner; Bernhard Erdlenbruch; Alfred Längler; Astrid Gnekow; Joachim Kühl; Michael Albani; Sigrid Völpel; Peter Bucsky; Angela Emser; Ove Peters; Johannes E A Wolff Journal: Cancer Date: 2004-04-15 Impact factor: 6.860
Authors: Johannes E A Wolff; Sabine Wagner; Marina Sindichakis; Thorsten Pietsch; Astrid Gnekow; Rolf-Dieter Kortmann; Ronald Sträter; Joachim Kuehl Journal: Anticancer Res Date: 2002 Nov-Dec Impact factor: 2.480
Authors: Barbara Dillinger; Sarah Ahmadi-Erber; Manuel Lau; Markus A Hoelzl; Friedrich Erhart; Birgit Juergens; Dietmar Fuchs; Andreas Heitger; Stephan Ladisch; Alexander M Dohnal Journal: Cell Immunol Date: 2018-02-02 Impact factor: 4.868
Authors: Johannes E A Wolff; Carl Friedrich Classen; Sabine Wagner; Rolf-Dieter Kortmann; Shana L Palla; Torsten Pietsch; Joachim Kühl; Astrid Gnekow; Christof M Kramm Journal: J Neurooncol Date: 2008-01-22 Impact factor: 4.130
Authors: Michael Karremann; Sandra Butenhoff; Ulrike Rausche; Torsten Pietsch; Johannes E A Wolff; Christof M Kramm Journal: Neuro Oncol Date: 2008-12-02 Impact factor: 12.300
Authors: Johannes E A Wolff; Christof Kramm; Rolf-Dieter Kortmann; Torsten Pietsch; Stefan Rutkowski; Norbert Jorch; Astrid Gnekow; Pablo Hernáiz Driever Journal: J Neurooncol Date: 2008-08-05 Impact factor: 4.130
Authors: Michael Karremann; Torsten Pietsch; Gisela Janssen; Christof M Kramm; Johannes E A Wolff Journal: J Neurooncol Date: 2008-11-29 Impact factor: 4.130